Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

In 5734 pts with chronic kidney disease (CKD) and type 2 diabetes, treatment with finerenone resulted in lower risks of CKD progression (40% baseline reduction eGFR or death from renal causes) vs placebo (follow up 2.6 yrs; 17.8% vs 21.1%; HR 0.82; 95% CI, 0.73 to 0.93; P=0.001).

SPS commentary:

Finerenone is an oral nonsteroidal, selective mineralocorticoid receptor antagonist, being investigated in CKD and type 2 diabetes.

New England Journal of Medicine